1133 related articles for article (PubMed ID: 9455711)
21. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
Glasser SP; Salas M; Delzell E
J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
[TBL] [Abstract][Full Text] [Related]
22. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
[TBL] [Abstract][Full Text] [Related]
24. New approaches in preclinical and clinical pharmacokinetics.
Graham MA; Kaye SB
Cancer Surv; 1993; 17():27-49. PubMed ID: 8137345
[TBL] [Abstract][Full Text] [Related]
25. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
26. [Responsibilities of clinical pharmacology in the early phase of drug development].
Kuhlmann J
Med Klin (Munich); 1999 May; 94(5):290-9. PubMed ID: 10408193
[TBL] [Abstract][Full Text] [Related]
27. Defining the role of pharmacology in the emerging world of translational research.
Enna SJ; Williams M
Adv Pharmacol; 2009; 57():1-30. PubMed ID: 20230758
[TBL] [Abstract][Full Text] [Related]
28. Strategy for the development of novel anticancer drugs.
Saijo N; Tamura T; Nishio K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
[TBL] [Abstract][Full Text] [Related]
29. [The origin of informed consent].
Mallardi V
Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
[TBL] [Abstract][Full Text] [Related]
30. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
Shah RR
Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
[TBL] [Abstract][Full Text] [Related]
31. [Tuberculosis and its control--lessons from the past and future prospect].
Shimao T
Kekkaku; 2005 Jun; 80(6):481-9. PubMed ID: 16130906
[TBL] [Abstract][Full Text] [Related]
32. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
33. Surgeons: A Future Role in Clinical Trials?
Rusch VW
Oncologist; 1997; 2(3):V-VI. PubMed ID: 10388050
[TBL] [Abstract][Full Text] [Related]
34. [From gene to drug: recent developments in medicinal chemistry].
de Esch IJ; Leurs R
Ned Tijdschr Geneeskd; 2008 Dec; 152(51-52):2795-800. PubMed ID: 19177921
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacokinetic and metabolic studies in the development of drugs].
Vereczkey L
Acta Pharm Hung; 1995 Jul; 65(4):105-11. PubMed ID: 7572191
[TBL] [Abstract][Full Text] [Related]
36. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
[TBL] [Abstract][Full Text] [Related]
37. Screening and evaluation of anticancer agents.
Zee-Cheng RK; Cheng CC
Methods Find Exp Clin Pharmacol; 1988 Feb; 10(2):67-101. PubMed ID: 3283480
[TBL] [Abstract][Full Text] [Related]
38. Approaches to the development and marketing approval of drugs that prevent cancer.
Kelloff GJ; Johnson JR; Crowell JA; Boone CW; DeGeorge JJ; Steele VE; Mehta MU; Temeck JW; Schmidt WJ; Burke G
Cancer Epidemiol Biomarkers Prev; 1995; 4(1):1-10. PubMed ID: 7894318
[TBL] [Abstract][Full Text] [Related]
39. [How to measure the kinetics of biological effect of a drug].
Lechat P; Canet E
Therapie; 1997; 52(4):291-8. PubMed ID: 9437880
[TBL] [Abstract][Full Text] [Related]
40. Drug development: from concept to marketing!
Tamimi NA; Ellis P
Nephron Clin Pract; 2009; 113(3):c125-31. PubMed ID: 19729922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
